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Abstract
This review gives an overview of the research on hypothalamopituitary dysfunction as a potential
consequence of traumatic brain injury, including the natural history of this complication and its clinical
and public health implications.
Introduction and context
With an overall incidence of 235 per 100,000 persons
per year, traumatic brain injury (TBI) is a major
public health problem [1]. In young adults, TBI is the
leading cause of death and disability [2]. Aneurysmal
subarachnoid hemorrhage (SAH) occurs in 6-10 per
100,000 persons each year [3]. Both TBI and SAH leave
many survivors with significant adverse physical and
psychologicalsequelae ofthetrauma[4,5].Inrecent years,
neuroendocrine dysfunction following TBI and aneurys-
mal SAH was reported with a much higher prevalence
than previously suspected. Untreated hypopituitarism is
associated with serious morbidity [6-9] and premature
mortality [10,11]. Serious and life-threatening adrenal
crises secondary to acute adrenocorticotropic hormone
deficiency in TBI patients have been highlighted in the
literature recently with significant improvement following
glucocorticoid replacement [12]. In addition, hypopitui-
tarism can aggravate the underlying physical and neurop-
sychiatric deficits often following TBI, leading to impaired
recovery and quality of life (Qol). Here, we review recent
investigations that provide relevant information on the
screening and management of these patients.
Recent advances
Prevalence
Aimaretti and colleagues [13] had reported a high
prevalence of hypopituitarism in patients after TBI
and SAH in a prospective multicentre study in over
100 patients. It was demonstrated that partial dysfunc-
tion may improve with time but that panhypopituitar-
ism, which occurred in 5% of patients, is irreversible.
Up to one-third of patients were left with pituitary
insufficiency; growth hormone deficiency was the most
common deficit, followed by hypogonadism. The
severity of brain injury did not influence the degree
of hypopituitarism. Faculty of 1000 member Ho, in an
evaluation [14] of that paper, states that clinicians
should always evaluate pituitary function following
brain injury. The largest systematic review on hypotha-
lamopituitary dysfunction following TBI and aneury-
smal SAH, published by Schneider and colleagues [15],
summarizes 19 studies comprising 1,137 patients.
The pooled prevalences of hypopituitarism in the
chronic phase after TBI and SAH were 27.5% and
47%, respectively. However, a large variation in
prevalence of hormone deficiencies was found in the
different studies. Possible reasons for this were patient
selection, study designs, and tests used. In an evalua-
tion [16] of that paper, Faculty of 1000 member
Marion states that, due to the surprisingly high
prevalence of hypopituitarism in that meta-analysis,
the routine for patients with TBI or SAH should
include pituitary screening prior to release from the
acute care hospital as well as periodical controlling
later on.
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brain injury
In the same systematic review, after pooling of all
relevant studies, severity of brain injury was found to be
associated with occurrence of hypopituitarism. Several
prospective studies with a follow-up of 1-3 years confirm
the results of previous retrospective analyses. Predictive
factors are analysed and correlated with outcome. In
these recent studies, an association between severity of
trauma and acute and long-term neuroendocrine con-
sequences could be demonstrated [17-21]. Further
potential risk factors identified were diffuse axonal
injury, basal skull fracture, and older age in one study
[22], and increased intracranial pressure and prolonged
intensive care unit stay in another study [19].
Natural course of post-traumatic hypopituitarism
Early neuroendocrine abnormalities were transient in
some patients, whereas less commonly, hypopituitarism
evolved over time in others. In one study, there was little
further change of endocrine function after 6 months after
trauma [23]. Two other studies showed independently
that, between 3 and 12 months after trauma, pituitary
function may either recover or worsen, the latter being
less common [13,24].
Clinical relevance
A study published in 2008 by Bavisetty and colleagues
[20] on chronic hypopituitarism after TBI focused on risk
assessment and relationship to outcome. Six to nine
months after TBI, 21% of their patients required
hormone replacement of at least one axis. Most common
and associated with more disability, depression, and
reduced Qol was growth hormone deficiency/growth
hormone insensitivity (occurring in 16%). Klose and
colleagues [25] demonstrated that post-traumatic hypo-
pituitarism is associated with an unfavourable body
composition and lipid profile and a decreased Qol
12 months after injury. In 2007, Bondanelli and
colleagues [26] found that anterior pituitary function
may predict functional and cognitive outcome in TBI
patients undergoing rehabilitation.
Implications for clinical practice
A significant percentage of trauma patients are currently
living with undiagnosed endocrinopathies. Routine early
screening for pituitary dysfunction in patients with TBI
and SAH is likely to improve the Qol for these patients
by detecting unexpected pituitary dysfunction and
leading to the provision of replacement hormone
therapy for a substantial number. Given the large
number of individuals who fall victim to TBI and SAH
each year, post-traumatic hypopituitarism becomes an
entity of major public health significance. Based on the
incidence of patients hospitalized for TBI and SAH
reported in the literature and the frequencies of
hypopituitarism in these patients, the incidence of
hypopituitarism caused by these disorders is estimated
to be more than 30 per 100,000 per year [6]. This by
far outnumbers all other well-recognized causes of
hypopituitarism [27]. Due to a potential selection bias,
this is (at present) only a rough estimate and should be
considered with caution. However, it is clear that a large
number of patients with hypopituitarism after TBI or
SAH remain undiagnosed and untreated. Yet further
studies are needed. Particularly, prospective clinical trials
to assess the effects and risks of hormone replacement in
these patients are still lacking.
Recommendations for screening
Since the sequelae of brain injury may mask the signs of
hypopituitarism, the threshold for endocrine assessment
should be low, and in cases of uncertainty, endocrine
assessment should be performed at least once. Also, in
patients with basal skull fractures, diffuse axonal injury,
increased intracranial pressure or prolonged intensive
care unit stay, pituitary assessment should be considered.
In the acute phase, cortisol deficiency should not be
missed. Screening for low basal cortisol should be
performed in patients with clinical signs suggestive of
hypopituitarism or the abovementioned risk factors.
Screening for further deficiencies, including stimula-
tion tests, should be performed in patients at risk after
3-6 months after trauma [15]. Close collaboration
between the neurosurgery, endocrinology, rehabilitation
medicine and other disciplines is essential in order to
ensure optimal delivery of care. If hypopituitarism is
detected, hormone replacement therapy should be given
as appropriate and has the potential to improve recovery,
rehabilitation and Qol for those patients. Systematic
therapy studies showing the benefits of optimal
hormone substitution are needed.
Abbreviations
Qol, quality of life; SAH, subarachnoid hemorrhage; TBI,
traumatic brain injury.
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